Trial Outcomes & Findings for Intravenous Fat Emulsions and Premature Infants (NCT NCT01096446)
NCT ID: NCT01096446
Last Updated: 2014-11-20
Results Overview
Each day the infants have a serum triglyceride level drawn to assess their tolerance of the intravenous fat emulsion being given.
TERMINATED
NA
19 participants
First 7 days of life
2014-11-20
Participant Flow
Infants with a birthweight \< 750 grams were recruited from April 2008 through March 2010 at the neonatal intensive care unit at at the Children's Hospital of Illinois at OSF Saint Francis Medical Center Peoria, IL.
Thirty-five infants were deemed eligible for the study of which 13 infants were excluded due to one parent refused, 12 other infants were started on TPN prior to obtaining informed consent.
Participant milestones
| Measure |
Higher Infusion
Infants randomized into the experimental group will receive 2 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
|
Standard Infusion
Infants randomized into the control group will receive 0.5 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
|
|---|---|---|
|
Overall Study
STARTED
|
12
|
10
|
|
Overall Study
COMPLETED
|
9
|
10
|
|
Overall Study
NOT COMPLETED
|
3
|
0
|
Reasons for withdrawal
| Measure |
Higher Infusion
Infants randomized into the experimental group will receive 2 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
|
Standard Infusion
Infants randomized into the control group will receive 0.5 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
|
|---|---|---|
|
Overall Study
Death
|
1
|
0
|
|
Overall Study
Protocol Violation
|
2
|
0
|
Baseline Characteristics
Intravenous Fat Emulsions and Premature Infants
Baseline characteristics by cohort
| Measure |
Standard Infusion
n=10 Participants
Infants randomized into the experimental group will receive 0.5 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
|
Higher Infusion
n=12 Participants
Infants randomized into the control group will receive 2 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
|
Total
n=22 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
10 Participants
n=5 Participants
|
12 Participants
n=7 Participants
|
22 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Age, Continuous
|
23.7 weeks
STANDARD_DEVIATION 0.68 • n=5 Participants
|
24.33 weeks
STANDARD_DEVIATION 1 • n=7 Participants
|
24 weeks
STANDARD_DEVIATION 0.5 • n=5 Participants
|
|
Sex: Female, Male
Female
|
5 Participants
n=5 Participants
|
9 Participants
n=7 Participants
|
14 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
5 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
8 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
10 participants
n=5 Participants
|
12 participants
n=7 Participants
|
22 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: First 7 days of lifePopulation: This study was ended early due to 100% of the infants in the experimental group developed hypertriglyceridemia of 200 mg/dl or greater
Each day the infants have a serum triglyceride level drawn to assess their tolerance of the intravenous fat emulsion being given.
Outcome measures
| Measure |
Higher Infusion
n=9 Participants
Infants randomized into the experimental group will receive 2 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
|
Standard Infusion
n=10 Participants
Infants randomized into the control group will receive 0.5 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
|
|---|---|---|
|
Number of Infants Serum Triglyceride Level Higher Than 200 mg/dl
|
9 participants
|
4 participants
|
SECONDARY outcome
Timeframe: First 2 weeks of lifeInfants in both groups weights were monitored to determine if giving higher infusions of intravenous fat emulsion helped the infants regain their birthweight sooner.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: First 14 days of LifeMonitored the calorie intake of infants to see which group was able to acheive 90 cal/kg/day from the total parenteral nutrition.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Entire hospital stayRecorded all infant's weights at discharge and plotted the anthropometric values on the Fenton Growth Charts.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: First 7 days of lifeInfants were monitored to see if insulin was started to control hyperglycemia.
Outcome measures
Outcome data not reported
Adverse Events
Serum Triglycerides
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place